Rituximab-associated immune myelopathy.

doi:10.1182/blood-2003-05-1532

PMID: 12900357DOI: 10.1182/blood-2003-05-1532Aug 6, 2003Paper

Rituximab-associated immune myelopathy.

Blood

Theodora PapadakiAthanasios Fassas

Abstract

No abstract listed.

References

Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies

Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I N MicallefA Z Rohatiner

CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes

Apr 15, 2000·Arthritis and Rheumatism·G CoakleyJ S Lanchbury

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment

Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·J BienvenuUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

May 15, 2002·Leukemia Research·T PapadakiK Stefanoudaki-Sofianatou

Anti-CD20-based therapy of B cell lymphoma: state of the art

Oct 3, 2002·Leukemia·C KosmasT Papadaki

Agranulocytosis unresponsive to growth factors following rituximab in vivo purging.

May 7, 2003·Blood·Andrea L RoseDavid G Maloney

❮ Previous

Next ❯

Citations

The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Dec 1, 2006·Current Hematologic Malignancy Reports·Elizabeth Naparstek

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

Jan 11, 2008·Leukemia·K StamatopoulosH A Papadaki

Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature

Sep 10, 2010·Medicine·Ofir WolachMeir Lahav

Neutropenia associated with rituximab therapy

Nov 26, 2010·Current Opinion in Hematology·Cliona GrantKieron Dunleavy

Neutropenia after rituximab treatment: new insights on a late complication

Nov 15, 2011·Current Opinion in Hematology·Ofir WolachMeir Lahav

Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab

Jan 6, 2009·Internal Medicine·Yasuo HirayamaJunji Kato

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone

Oct 11, 2013·ISRN Neurology·Evgeniy EvdoshenkoAmit Bar-Or

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

Jul 15, 2006·Leukemia & Lymphoma·Chiara CattaneoGiuseppe Rossi

Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review

Dec 16, 2006·Leukemia & Lymphoma·Boo MessahelRoss Pinkerton

Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

Nov 15, 2011·Expert Review of Hematology·Daniel Tesfa, Jan Palmblad

Rituximab-associated neutropenia.

Mar 31, 2010·Seminars in Hematology·Kieron DunleavyWyndham H Wilson

Review of the current use of rituximab during 4 years in a French university hospital

Sep 1, 2015·La Revue de médecine interne·Q ReynaudP Cathébras

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy

Sep 24, 2005·Journal of Cutaneous Pathology·Yeshwant B RawalCynthia M Magro

Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases

Oct 21, 2004·American Journal of Hematology·Elpis MantadakisMaria Kalmanti

Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma

May 6, 2009·American Journal of Hematology·Gillianne Geet Yi LaiRichard Quek

Rituximab: a original biotherapy in auto-immune disorders

Jun 7, 2005·La Revue de médecine interne·J Sibilia, C Sordet

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

Nov 20, 2013·Oncoimmunology·Brian A Baldo

Cytotoxic T cells in chronic idiopathic neutropenia express restricted antigen receptors

May 24, 2017·Leukemia & Lymphoma·Semeli MastrodemouKostas Stamatopoulos

Tumour-associated neutrophils in patients with cancer

Jun 5, 2019·Nature Reviews. Clinical Oncology·Merav E Shaul, Zvi G Fridlender

Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.

Jul 22, 2021·Leukemia & Lymphoma·Shai ShimonyOfir Wolach

❮ Previous

Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Rituximab-associated immune myelopathy.

Abstract

References

Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies

CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

Anti-CD20-based therapy of B cell lymphoma: state of the art

Agranulocytosis unresponsive to growth factors following rituximab in vivo purging.

Citations

The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature

Neutropenia associated with rituximab therapy

Neutropenia after rituximab treatment: new insights on a late complication

Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review

Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms

Rituximab-associated neutropenia.

Review of the current use of rituximab during 4 years in a French university hospital

The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy

Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases

Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma

Rituximab: a original biotherapy in auto-immune disorders

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

Cytotoxic T cells in chronic idiopathic neutropenia express restricted antigen receptors

Tumour-associated neutrophils in patients with cancer

Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity.

Related Concepts

Related Feeds

B-Cell Lymphoma

Related Papers

Neutropenia in patients treated with rituximab

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

Interstitial pneumonitis related to rituximab therapy

Delayed-onset neutropenia associated with rituximab therapy

Agranulocytosis unresponsive to growth factors following rituximab in vivo purging.